广东省胃肠病学研究所

1.Zhuang Z#, Lin J#, Wan Z#, Weng J, Yuan Z, Xie Y, Liu Z, Xie P, Mao S, Wang Z, Wang X, Huang M, Luo Y and Yu H*. Radiogenomic profiling of global DNA methylation associated with molecular phenotypes and immune features in glioma. BMC Med 22, 352 (2024).
2.Cai J#, Lin K#, Luo T#, Weng J, Liu H, Yuan Z, Wan Z, Han J, Lin J, Liu X, Wang X, Huang M, Luo Y and Yu H*. Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial. Br J Cancer. 2024 May;130(9):1434-1440.
3.Yu H#, Wang X, Bai L, Tang G, Carter KT, Cui J, Huang P, Liang L, Ding Y, Cai M, Huang M, Liu H, Cao G, Gallinger S, Pai RK, Buchanan DD, Win AK, Newcomb PA, Wang JP*, Grady WM*, Luo Y*. DNA Methylation Profile in CpG-depleted Genomic Region Uncovers an Epigenetic Subtype with High Risk of Recurrence in Early-stage Colorectal Cancer. J Natl Cancer Inst. 2023 Jan 10;115(1):52-61.
4.Shen D#, Lin J#, Xie Y, Zhuang Z, Xu G, Peng S, Tang G, Bai L, Zhu M, Zhang Y, Huang Z, Wang P, Liu X, Huang M, Luo Y*, Wang X*, Yu H*. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner. Clin Transl Med. 2023 May;13(5):e1279.
5.Xie Y#, Lin J#, Zhang N#, Wang X, Wang P, Peng S, Li J, Wu Y, Huang Y, Zhuang Z, Shen D, Zhu M, Liu X, Liu G, Meng X, Huang M, Yu H*, Luo Y*. Prevalent Pseudoprogression and Pseudoresidue in Rectal Cancer Patients Treated with Neoadjuvant Immune Checkpoint Inhibitors. J Natl Compr Canc Netw. 2023 Feb;21(2):133-142.e3.
6.Cao X#, Li W, Wang T, Ran D, Davalos V, Planas-Serra L, Pujol A, Esteller M, Wang X, Yu H*. Accelerated biological aging in COVID-19 patients. Nat Commun. 2022 Apr 19;13(1):2135.
7.Shen D#, Wang X, Wang H, Xu G, Xie Y, Zhuang Z, Huang Z, Li J, Lin J, Wang P, Huang M, Luo Y, Yu H*. Current Surveillance After Treatment is Not Sufficient for Patients With Rectal Cancer With Negative Baseline CEA. J Natl Compr Canc Netw. 2022 Mar 1:1-10.
8.Zou Q#, Wang X#, Ren D#, Hu B, Tang G, Zhang Y, Huang M, Pai RK, Buchanan DD, Win AK, Newcomb PA, Grady WM, Yu H*, Luo Y*. DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. J Immunother Cancer. 2021;9.
9.Yu H#, Bai L, Tang G, Wang X, Huang M, Cao G, Wang J, Luo Y*. Novel Assay for Quantitative Analysis of DNA Methylation at Single-Base Resolution. Clin Chem. 2019;65:664-673.
10.Yu H#, Luo Y*. Decentered Crowdfunded Clinical Studies-Open a New Era of Medical Research. JAMA Oncol. 2019;5:9-10.
11.Li L#, Xu B#, Zhuang Z#, Li J, Hu Y, Yang H, Wang X, Lin J, Zhou R, Chen W, Ran D, Huang M, Wang D*, Luo Y*, Yu H*. Accurate tumor segmentation and treatment outcome prediction with DeepTOP. Radiother Oncol. 2023 Feb 21;183:109550.
12.Wang X#, Chen S#, Zhao Z, Chen F, Huang Y, Guo X, Lei L, Wang W, Luo Y, Yu H*, Wang J*. Genomic G-quadruplex Folding Triggers a Cytokine-mediated Inflammatory Feedback Loop to Aggravate Inflammatory Diseases. iScience. 2022.
13.Chen Z#, Huang Z#, Luo Y, Zou Q, Bai L, Tang G, Wang X, Cao G, Huang M, Xiang J*, Yu H*. Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer. J Transl Med. 2021;19:73.
14.Xie Y#, Lin J#, Wang X, Wang P, Zhuang Z, Zou Q, Cai D, Huang Z, Bai L, Tang G, Huang M, Wang J, Yu H*, Luo Y*. The Addition of Preoperative Radiation Is Insufficient for Lateral Pelvic Control in a Subgroup of Patients with Low Locally Advanced Rectal Cancer: A Post-Hoc Study of a Randomized Controlled Trial. Dis Colon Rectum. 2021.
15.Zhuang Z#, Liu Z#, Li J#, Wang X, Xie P, Xiong F, Hu J, Meng X, Huang M, Deng Y, Lan P, Yu H*, Luo Y*. Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer. J Transl Med. 2021;19:256.
16.Li X#, Cai D, Huang Y, Xie Y, Shen D, Yuan Z, Liu X, Huang M, Luo Y, Yu H*, Wang X*. Aberrant methylation in neurofunctional gene serves as a hallmark of tumorigenesis and progression in colorectal cancer. BMC Cancer. 2023 Apr 6;23(1):315.
17.Zhao Z#, Lin J#, Chen S#, Wang X, Wang H, Xu G, Wang J, Zhou R, Huang Z, Li Y, Zhang Y, Liu X, Wang P, Huang M, Luo Y, Yu H*. Clinical atlas of rectal cancer highlights the barriers and insufficient interventions underlying the unfavorable outcomes in older patients. Heliyon. 2023;9.
18.Hu Y#, Li J#, Zhuang Z#, Xu B#, Wang D*, Yu H*, Li L*. Automatic treatment outcome prediction with DeepInteg based on multimodal radiological images in rectal cancer. Heliyon. 2023 Jan 25;9(2):e13094.
19.Shen D#, Wang P#, Xie Y, Zhuang Z, Zhu M, Wang X, Huang M, Luo Y, Yu H*. Clinical spectrum of rectal cancer identifies hallmarks of early-onset patients and next-generation treatment strategies. Cancer Med. 2022.
20.Cao X#, Wang X, Wang H, Xu G, Yu H*. Systemic Inflammation Status Relates to Anti-Inflammatory Drug Benefit and Survival in Rectal Cancer. J Surg Res. 2022 Jan;269:249-259.
21.Li J#, Xie Y#, Huang Z, Shen D, Zhuang Z, Zhu M, Huang Y, He R, Wang X, Huang M, Luo Y, Yu H*. Current treatment and surveillance modalities are not sufficient for advanced stage III colon cancer: Result from a multicenter cohort analysis. Cancer Med. 2021;10:8924-8933.
22.Zhuang Z#, Wang X#, Huang M, Luo Y*, Yu H*. Serum calcium improved systemic inflammation marker for predicting survival outcome in rectal cancer. J Gastrointest Oncol. 2021;12:568-579.
23.Huang Z#, Wang X, Zou Q, Zhuang Z, Xie Y, Cai D, Bai L, Tang G, Huang M, Luo Y*, Yu H*. High platelet-to-lymphocyte ratio predicts improved survival outcome for perioperative NSAID use in patients with rectal cancer. Int J Colorectal Dis. 2020;35:695-704.
24.Zou Q#, Ren D#, Wang X, Bai L, Tang G, Huang M, Luo Y*, Yu H*. Improved Survival Outcome and Access to Cancer Screening from Hemorrhoid in Patients with Rectal Cancer. Gastroenterol Res Pract. 2020;2020:5045142.
25.Yu HC#, Luo YX*, Peng H, Wang XL, Yang ZH, Huang MJ, Kang L, Wang L, Wang JP*. Association of perioperative blood pressure with long-term survival in rectal cancer patients. Cancer Commun. 2016;35:38.
26.Yu HC#, Luo YX*, Peng H, Kang L, Huang MJ, Wang JP*. Avoiding perioperative dexamethasone may improve the outcome of patients with rectal cancer. Eur J Surg Oncol. 2015;41:667-673.
27.Yu HC#, Peng H#*, He XS, Zhao RS. Comparison of short- and long-term outcomes after extralevator abdominoperineal excision and standard abdominoperineal excision for rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2014;29:183-191.
28.禹汇川#, 骆衍新, 王小琳, 康亮, 黄美近, 邓艳红, 王磊, 汪建平*. 直肠癌根治术后的复发类型对复发后远期生存的影响. 中华医学杂志. 2016;96:625-628.

1.国家自然科学基金，面上项目，82473456
2.国家自然科学基金，面上项目，82272965
3.国家自然科学基金，青年项目，81902877
4.广东省自然科学基金，面上项目，2022A1515012656
5.广东省自然科学基金，面上项目，2018A0303130303
6.广东省自然科学基金，青年项目，2016A030310222
7.广州市科技计划项目，一般项目，202201011004

8.中山大学高校基本科研业务费，创新人才培育计划项目（青年拔尖人才培育项目），23ykbj007

发明专利：
1. 禹汇川，骆衍新，白亮亮，唐冠楠，王小琳，李英杰，黄增鸿，黄美近，汪建平. 一种DNA甲基化定量系统，发明专利，ZL201810845927.3，2018年07月27日，2019年12月24日，中山大学附属第六医院、中山大学
2. 禹汇川，骆衍新，邹齐，王小琳，申鼎成，任东林，唐冠楠，张宇，黄美近. 用于评估组织免疫反应和诊断预后的DNA甲基化检测试剂盒，发明专利，ZL202011176816.1，2020年10月29日，2022年09月02日，中山大学附属第六医院、中山大学
3. 禹汇川，骆衍新，白亮亮，唐冠楠，王小琳，黄品助，黄安培，李英杰，黄美近，王磊，汪建平. KAZN基因甲基化检测试剂在制备结直肠癌预后诊断试剂中的应用，发明专利，ZL201910045367.8，2019年01月17日，2023年08月01日，中山大学附属第六医院、中山大学
4. 禹汇川，骆衍新，白亮亮，唐冠楠，王小琳，黄品助，黄安培，李英杰，黄美近，王磊，汪建平. FAT3基因甲基化检测试剂在制备结直肠癌预后诊断试剂中的应用，发明专利，ZL201910045385.6，2019年01月17日，2023年08月01日，中山大学附属第六医院、中山大学
5. 禹汇川，骆衍新，白亮亮，唐冠楠，王小琳，黄品助，黄安培，李英杰，黄美近，王磊，汪建平. DUSP3基因甲基化检测试剂在制备结直肠癌预后诊断试剂中的应用，发明专利，ZL201910045812.0，2019年01月17日，2023年08月11日，中山大学附属第六医院、中山大学

禹汇川(副研究员 硕士生导师)

禹汇川(副研究员硕士生导师)